European Growth Stocks Insiders Are Investing In
April 16, 2025
In recent weeks, European markets have experienced heightened volatility due to escalating trade tensions, with major indices such as the STOXX Europe 600 Index seeing declines. Amid this uncertainty, growth companies with high insider ownership can present intriguing opportunities for investors, as insider investment often signals confidence in a company’s long-term potential despite short-term market fluctuations.
|
Name |
Insider Ownership |
Earnings Growth |
|
Pharma Mar (BME:PHM) |
11.8% |
40.8% |
|
Vow (OB:VOW) |
13.1% |
111.2% |
|
Elicera Therapeutics (OM:ELIC) |
20.5% |
97.2% |
|
Bergen Carbon Solutions (OB:BCS) |
12% |
50.8% |
|
CD Projekt (WSE:CDR) |
29.7% |
37.4% |
|
Devyser Diagnostics (OM:DVYSR) |
35.7% |
96.5% |
|
Elliptic Laboratories (OB:ELABS) |
22.6% |
88.2% |
|
Lokotech Group (OB:LOKO) |
13.9% |
58.1% |
|
Nordic Halibut (OB:NOHAL) |
29.8% |
60.7% |
|
Ortoma (OM:ORT B) |
27.7% |
68.6% |
Here we highlight a subset of our preferred stocks from the screener.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Ambu A/S is a medical technology company that develops, produces, and sells medical devices to hospitals, clinics, and rescue services globally, with a market capitalization of DKK31.41 billion.
Operations: The company’s revenue is primarily derived from its Disposable Medical Products segment, which generated DKK5.65 billion.
Insider Ownership: 24.9%
Ambu is poised for significant earnings growth, with forecasts indicating a 25.44% annual increase over the next three years, outpacing the Danish market’s 8.4%. Despite trading at 9.3% below its estimated fair value and having no recent insider transactions, Ambu reported strong first-quarter results with sales of DKK 1.51 billion and net income of DKK 183 million, doubling from the previous year. However, its Return on Equity is expected to remain modest at 14.2%.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Surgical Science Sweden AB (publ) specializes in developing and marketing virtual reality simulators for evidence-based medical training globally, with a market cap of SEK6.67 billion.
Operations: The company’s revenue is derived from two main segments: Industry/OEM, contributing SEK441.59 million, and Educational Products, generating SEK442.50 million.
Insider Ownership: 26.6%
Surgical Science Sweden is set for robust growth, with earnings projected to rise 37.1% annually over the next three years, surpassing the Swedish market’s 13.4%. Despite a decline in profit margins from 26.5% to 14.9%, revenue is forecasted to grow at a substantial rate of 19.7% per year. Recent expansion into defense markets through a US$4.7 million order underscores its strategic diversification efforts, though insider trading activity remains minimal over recent months.
-
Take a closer look at Surgical Science Sweden’s potential here in our earnings growth report.
-
Our valuation report here indicates Surgical Science Sweden may be undervalued.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Straumann Holding AG offers tooth replacement and orthodontic solutions globally, with a market cap of CHF15.66 billion.
Operations: The company generates revenue from several regions, with CHF1.32 billion from operations, CHF592.70 million from Asia Pacific, CHF791.79 million from North America, CHF290.28 million from Latin America, and CHF1.11 billion from Europe, the Middle East and Africa.
Insider Ownership: 32.3%
Straumann Holding’s earnings are set to grow at 14.03% annually, outpacing the Swiss market’s 11%. The company’s revenue is also expected to rise faster than the market at 9.7% per year. Recent innovations like Straumann AXS enhance its digital workflow, potentially boosting growth prospects. Despite no significant insider trading activity recently, strategic leadership changes with Isabelle Adelt as CFO and Grant Bester overseeing North America could influence future performance positively.
-
Dive into the specifics of Straumann Holding here with our thorough growth forecast report.
-
Our expertly prepared valuation report Straumann Holding implies its share price may be too high.
-
Click here to access our complete index of 216 Fast Growing European Companies With High Insider Ownership.
-
Seeking Other Investments? Trump’s oil boom is here — pipelines are primed to profit. Discover the 20 US stocks riding the wave.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include CPSE:AMBU B OM:SUS and SWX:STMN.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Terms and Privacy Policy
Search
RECENT PRESS RELEASES
Related Post
